Presentations Included: - Session 1 Opening: Setting the Scene for Screening - Major Efforts Worldwide
- Suzette Delaloge, MD, MSc, Gustave Roussy
- WISDOM 1.0: Review of Findings, Opportunities and Challenges
- Laura Esserman, MD, MBA, University of California, San Francisco
- Genetic Findings in WISDOM 1.0
- Kirkpatrick Fergus, MD, MAS, University of California, San Francisco
- WISDOM and MyPeBS: Personalized breast cancer screening trials operating in distinct international contexts
- Katherine Leggat-Barr, BS, Tufts University School of Medicine
- National cost of the WISDOM study risk-based breast cancer screening algorithm with comparison to advocated guidelines
- Kimberly Badal, PhD, University of California, San Francisco
- Risk Stratified Breast Cancer Screening: Early Outcomes and Psychological Impact from PRSONAL – a Randomized Clinical Trial
- Stig Bojesen, University of Copenhagen
|
Presentations Included: - Spatial Transcriptomics and sc-RNA-seq of Drug Tolerant Persister Cells and unaffected cancer cells in Ovarian Cancer after neoadjuvant-chemotherapy
- Joshua Barkin, BS, University of California, Davis
- A Patient Advocate's Perspective
- Valerie Fraser, SWOG Cancer Research Network-Patient Advocates Committee
|
Session 3: Early Imaging Endpoints to Accelerate the Learning Cycle (Risk Assessment and Response)To be added... |
Presentations Included: - Mammogram Image-Based Risk: A response biomarker for trials?
- Graham Colditz, MD, DrPH, Washington University
- Biomarker selection for an early phase prevention trial comparing two selective estrogen receptor modulators: Acolbifene vs Low Dose Tamoxifen
- Bruce Kimler, PhD, FRRS The University of Kansas Medical Center
- ctDNA: Let the Patient Decide?
- Amy L. Delson, AIA, UCSF Breast Science Advocacy Core
|
Presentations Included: - MDA20-02-01 Time restricted Eating And Metformin (TEAM) in invasive breast cancer (IBC) or ductal carcinoma in situ (DCIS). A randomized, phase IIb, window of opportunity presurgical trial
- Andrea De Censi, MD, Champalimaud Clinical Centre
- A Pilot Prevention Study of the Effects of the Anti-progestin Ulipristal Acetate (UA) on Surrogate Markers of Breast Cancer Risk
- Sacha Howell, PhD, The University of Manchester
- Low dose TamOxifen and LifestylE changes for bReast cANcer prevenTion: a randomized phase II biomarker trial in subjects at increased risk (TOLERANT Study)
- Davide Serrano, European Institute of Oncology
- Early Results from a Phase 1 Clinical Trial of a Cancer Vaccine Targeting Tumor Associated Antigen MUC1 for Immune Interception of Breast Cancer in Patients with Ductal Carcinoma in Situ
- Emilia Diego, MD, University of Pittsburgh
|
Presentations Included: - Welcome and global perspective on access to reproductive healthcare
- Daniel Grossman, MD, University of California, San Francisco
- Capturing shifts in abortion care post-Dobbs
- Ushma Upadhyay, PhD, MPH, University of California, San Francisco
- Providing comprehensive reproductive and pregnancy care to breast cancer patients
- Lynn Yee MD, MPH, Northwestern University Feinberg School of Medicine
- The Illinois CARLA program, a model for abortion care access
- Jonah Fleisher, MD, MPH, University of Illinois – Chicago
- Hearing from patients – perspectives from ACESSS Reproductive Justice
- Jessica Pinckney Gil, ACCESS Reproductive Justice
|
Presentations Included: - Where stigma and evidence collide: considerations for creative applications of ulipristal acetate emergency contraception
- Abigail Liberty, MD, MSPH, Oregon Health & Science University
- Can treatment of uterine fibroid provide a path for breast cancer Prevention?
- Mervat Omran, B.pharm, MS, MD/PhD, University of Chicago
- A randomized trial of UPA vs a COC "UPA drastically lowers breast cell proliferation” (& RCT of UPA contraceptive phase 1-2)
- Carolyn Westhoff, MD, MSc, Columbia University
- Hormonal cancer prevention in premenopausal women: reducing ovarian hormone exposure while preserving fertility
- Jeffrey N. Weitzel, MD, University of Kansas Comprehensive Cancer Center
|
Session 8: Interaction of Pregnancy and Breast Cancer: Translational Opportunities to Accelerate Improving OutcomePresentations Included: - Session Introduction – Why talk about Pregnancy and Breast Cancer?
- Virginia Borges, MD, University of Colorado
- Pregnancy Factors and Breast Cancer Risk by Familial Risk within the Breast Cancer Family Registry
- Jasmine McDonald, PhD, Columbia University Irving Medical Center
- Prevention of PPBC via novel detection methods: Beyond Blood: Can Breast Milk ctDNA Enable Earlier Detection of PPBC?
- Cristina Saura, MD, PhD, Vall d’Hebron University Hospital
- Pregnancy after Breast Cancer – is it protective?
- Matteo Lambertini, MD, PhD, University of Genova
|
Presentations Included: - Innovative Strategies to Scale Personalized Prevention
- Olufunmilayo Olopade, MD, University of Chicago
- Breast Cancer Champions: Meeting you where you live
- David Haynes, PhD, University of Minnesota
- Introducing Clinical Hope - A Paradigm Shifting Approach to Clinical Trials
- Zhonnet Harper, Alameda County Public Health Commission
- A Patient Advocate's Perspective
- Ricki Fairley, TOUCH, The Black Breast Cancer Alliance
|
Presentations Included: - The History of Environmental Exposures and Breast Cancer
- Mary Beth Terry, PhD, Professor of Epidemiology and Environmental Sciences at Columbia University, Executive Director of Silent Spring Institute
- The Breast Cancer Exposome: Uncovering the Role of Environmental Chemicals
- Alexandra White, PhD, MSPH, National Institute of Health
- From Science to Policy
- Nancy Buermeyer, Breast Cancer Prevention Partners
|
Session 11: Lifestyle-based Prevention Strategies Presentations Included: - May the Fiber Be With You: Cultivating a healthy microbiome
- Katrine Whiteson, PhD, University of California, Irvine
- Diet and the Microbiome-Gut-Brain Axis: The Role in Health and Disease
- Leigh A. Frame, PhD, MSH, The George Washington University
- Increased fatty acid availability drives metabolic dysregulations associated with tumorigenic breast remodeling
- Mariana Bustamente Eduardo, PhD, Feinberg School of Medicine, Northwestern University
- Moving On: Empowering Lifestyle Change
- Elisabeth Watson, UCSF Breast Health Clinic Volunteer
|
Session 12: Treating Obesity / Obesity in the Context of the Larger Hormonal Picture Presentations Included: - Microbiome in Obesity
- Katherine Cook, PhD, Wake Forest University
- Obesity causes dysregulation of immune memory and loss of protection following therapeutic vaccination for breast cancer
- Erika J. Crosby, PhD, Duke University Medical Center
- Comparative Effects of Semaglutide vs Tirzepatide on Weight Change and Cardiovascular Risk in Breast Cancer Survivors
- Jasmine Hundal, MD, MS, MPH, Cleaveland Clinic
- A Patient Advocate's Perspective
- Julia Laursen, For the Four
|
Session 13: Menopausal Hormone Therapy and Alternatives for Women at High Risk for Breast CancerPresentations Included: - An evidence-informed approach to MHT in women at high risk
- Lisa Larkin, MD, FACP, MSCP, Ms. Medicine & Erin Duralde, MD, MPH, MSCP, One Medical
|
Session 14: Menopausal Hormone Therapy and Alternatives for Women with Breast CancerPresentations Included: - From the front lines of gynecology: bridging evidence, advocacy, and social media about HRT after breast cancer
- Abigail Liberty, MD, MSPH, Oregon Health & Science University
- Why Early Conversations and Ongoing Care Matter for Menopause After Breast Cancer
- Jane Mortimer, UCSF Breast Science Advocacy Core
- Clinical Insights Informing Management Strategies in Breast Cancer Survivors
- Mindy Goldman, MD, Midi Health
|